Printer Friendly

RTI introduces next generation of BioCleanse, restructures agreement with MSD.

Regeneration Technologies, Inc. (RTI), Alachua, FL announced it has introduced the next-generation of its BioCleanse tissue sterilization system. The company says the new system sterilizes tissue from a single donor in one of several individual processing units, thus eliminating the need to batch tissue from multiple donors during the sterilization process.

The BioCleanse system is a low temperature chemical sterilization process that eliminates bacteria, fungi and spores, as well as enveloped and non-enveloped viruses such as HIV and hepatitis from tissue, without altering the strength or biocompatibility of the allograft, RTI says. Earlier this year the FDA completed a compliance review of the process and determined that RTI had successfully validated the process. (Transplant News, February 27, 2002)

RTI also announced it has agreed to new terms with Medtronic Sofamor Danek (MSD) for an exclusive license and distribution agreement to supply human allograft tissue and bone paste for spine surgery.

MSD will continue to serve as exclusive worldwide distributor for specialty tissue allografts and bone paste processed by RTI for use in spinal surgery. Under the new agreement, the companies have agreed to co-develop new tissue-based spine surgery solutions and restructure financial terms to reflect the value of RTI's proprietary technology including its BioCleanse process.

Contact: Quenta Vettel - (386) 318-8888
COPYRIGHT 2002 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Medtronic Sofamor Danek
Comment:RTI introduces next generation of BioCleanse, restructures agreement with MSD.(Medtronic Sofamor Danek)
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 12, 2002
Words:210
Previous Article:CryoLife admits misstatements contained in press release about FDA warning letter.
Next Article:LifeCell, LifeNet and Arthrex team up to deliver acceluar allografts for sports medicine.
Topics:


Related Articles
FDA recommends Regeneration stop using BioCleanse over "safety concerns", company seeks meeting to clarify charges.
Regeneration Technologies to continue using BioCleanse sterilization process pending further review by FDA.
Regeneration Technologies gets FDA's blessing to continue using its BioCleanse process following exchange of letters.
FDA concludes Regeneration Technologies BioCleanse tissue sterilization process needs no regulatory action.
RTI, Osteotech announce settlement of lawsuit over bone dowel patent.
Medtronic acquires European rights to market genetically engineered bone formation inducing protein.
FDA approves Wyeth recombinant protein bone treatment for tibia fractures.
Whistleblower, doctors decry medical industry kickbacks.
Medtronic files patent suit against NuVasive.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters